Telikibart shows ‘promising efficacy’ for moderate to severe eczema

Дата публикации: 16-10-2026 13:22:05

Telikibart demonstrated promising efficacy in the treatment of adults with moderate to severe atopic dermatitis, according to a presentation at the European Academy of Dermatology and Venerology Congress.Telikibart (GR1802, Genrix) is a fully human monoclonal antibody that suppresses type 2-driven inflammation by inhibiting interleukin-4 and -13.“AD is one of the most widespread diseases in the world,” Shangshang Wang, MD, PhD, associate chief physician in the department of dermatology at Huashan Hospital, Fudan University in Shanghai, said during the presentation. “AD is characterized by

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Lebrikizumab relieves ‘debilitating’ symptoms of hand, foot dermatitis in phase 3 study	0	6.93	15-10-2026
2	Tezepelumab curbs asthma exacerbations across neutrophil counts	0	10.18	20-10-2026
3	Biologics linked to fewer cardiovascular events in severe asthma	0	9.34	19-10-2026
4	Quality of life improves in asthma with depemokimab	0	11.79	20-10-2026
5	Xolair biosimilar Omlyclo commercially available in US	0	9.38	21-10-2026
6	Tezepelumab sustains EoE remission, dysphagia relief at 52 weeks	0	9.54	22-10-2026
7	Most patients with severe asthma switch or discontinue biologics	0	9.97	19-10-2026
8	FDA OKs Orladeyo berotralstat pellets for hereditary angioedema	0	9.81	23-10-2026
9	Weight loss drugs may literally be saving people's arms and legs	5	7	06-07-2026
10	À qui s’adresse le nouveau candidat vaccin contre le cancer de la peau ? “Ces dernières années, on a progressé remarquablement”	0	7.01	21-08-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 8.01. Источник: www.healio.com.